We also found that PLD1 and phospho-Akt are coexpressed in some breast tumours, a fact which could complicate the utility of rapamycin-based therapies, as patients expressing both proteins could differ in sensitivity to mTOR inhibitors. Here, PLD1 is linked to breast neoplasm.